SOD1 and amyotrophic lateral sclerosis: The many studies discussed here have clearly proven the potential of AAV-RNAi gene therapy for treating SOD1-ALS, and this approach is now also being applied to other ALS causative genes (Peters et al., 2015a), but more potent delivery vehicles are still needed to simultaneously target all disease-relevant CNS populations in adults.